Very little is known about patient, provider, and facility characteristics that may affect the likelihood that a schizophrenia patient who receives an antipsychotic medication is dosed according to treatment recommendations. In this study, prescription drug records for schizophrenia patients were collected from the Department of Veterans Affairs, and indicators were constructed describing whether the average daily dose was outside of the range recommended by the schizophrenia Patient Outcomes Research Team (PORT). Generalized estimation equations were used to identify patient, facility, and provider characteristics that are associated with adherence to PORT recommendations. We found that the majority (62.1%) of patients were dosed within the PORT-recommended dosing range. Patients who were older, were female, had comorbid psychiatric disorders, or were prescribed conventional antipsychotics were less likely to adhere to PORT recommendations. Provider and facility characteristics were generally not significantly associated with adherence. When patients were dosed outside of the recommendations, patients treated at facilities with more emphasis on mental health and research and education were more likely to be dosed above the recommendations.
Antipsychotic pharmacotherapy is a cornerstone of effective treatment for schizophrenia. Conventional antipsychotic medications, while highly effective, have a number of unpleasant extrapyramidal side effects. Newer, atypical antipsychotics have fewer of these side effects but have been associated with other side effects, such as weight gain and diabetes (Sernyak et al. 2002) . These side effects can become more severe as dosages increase, often with little or no increases in effectiveness (Baldessarini et al. 1988; Citrome and Volavka 2002) .
With the recent focus on reducing health care costs, there is increasing concern that the quality of care be monitored and maintained. There are a number of published treatment recommendations and guidelines for the treatment of schizophrenia, including one developed by the schizophrenia Patient Outcomes Research Team (PORT) (Lehman et al. 1998) . Like some other treatment recommendations, the PORT recommendations specify dosing ranges for each of the antipsychotic medications on the market. Previous research has used adherence to these dosing recommendations as a measure of the quality of pharmacotherapeutic care for schizophrenia (Leslie and Rosenheck 2000 , 2001a , 2001c .
Very little is known, however, about what factors affect whether a patient is dosed according to treatment recommendations and guidelines. Previous research suggests that almost 40 percent of patients with schizophrenia who receive antipsychotic medications are dosed outside of the PORT-recommended dosing range Rosenheck 2001ft, 2001c) . If this is considered poor-quality care, more information about which patients are at risk for relatively high or low dosing can help inform policies to improve the quality of care for these patients.
However, the issue of whether adherence to dosing recommendations and guidelines can be used as a quality measure is not straightforward. Despite the existence of treatment recommendations that include recommended dosing ranges, such as the PORT and the Texas Medication Algorithm Project (Miller et al. 1999) , broad consensus about the appropriate dosing ranges is lacking (Tauscher and Kapur 2001) , and what is considered to be a high dose changes over time as clinical experience and research accumulate (Citrome and Volavka 2002) . While treatment recommendations and guidelines are based on the best clinical evidence available (Milner and Valenstein Send reprint requests to Dr. D.L. Leslie, Yale University School of Medicine, NEPEC/182, 950 Campbell Ave., West Haven, CT 06516; email: douglas.leslie@yale.edu.
2002), the studies on which they are based often used somewhat arbitrarily chosen doses to determine the most efficient range for a given patient population (Tauscher and Kapur 2001) . Given the uncertainty surrounding what is considered an appropriate dose, it is difficult to determine whether dosing outside of the PORT recommendations represents poor-quality care or highlights the limitations of using adherence to recommendations and guidelines as a quality measure. Nevertheless, it is important to understand factors that affect whether a patient is dosed outside of the recommended range.
This study used data from the Department of Veteran Affairs (VA) to investigate patient, provider, and facility characteristics that affect whether a patient with schizophrenia receives an antipsychotic medication dose that adheres to the PORT recommendations. Furthermore, the study examined factors that affect whether patients are dosed higher or lower than the PORT-recommended range when the PORT dosing recommendations are not followed. We were particularly interested in whether the type of provider (physician vs. nonphysician and mental health vs. non-mental health specialist) affects adherence to dosing recommendations. We hypothesized that patients treated by physicians, by mental health specialists, or at facilities with greater emphasis on mental health care or research and education would be more likely to adhere to dosing recommendations.
Methods
Sources of Data. Data for the study come from national VA administrative data bases. The outpatient encounter file is a national data base of information concerning all VA outpatient clinic stops. Using this data base, we first identified all VA outpatients diagnosed with schizophrenia during fiscal year (FY) 2000 (October 1, 1999 , to September 30, 2000 . Patients were identified as being diagnosed with schizophrenia if they had at least two outpatient encounters in a specialty mental health outpatient clinic with a primary or secondary diagnosis of schizophrenia (ICD-9 codes 295.00-295.99) during the year. We required at least two diagnoses to ensure that the diagnosis of schizophrenia was reliable. Information on other comorbid mental health disorders was also collected from the outpatient care file. We restricted the sample to outpatients because inpatient and outpatient treatment of schizophrenia are quite different. Because only about 20 percent of patients with schizophrenia are treated in an inpatient setting, we chose to study outpatient prescription patterns.
Next, all outpatient prescription drug records for these patients during FY 2000 were collected from the VA Drug Benefit Management System in Hines, Illinois. Because nurses dispense depot medications on site in their clinics without specific prescriptions, we do not have patient-level information for depot drugs. Hence, only prescriptions for oral medications are included in the data set. Because patients could receive medications outside of the VA system, our final sample includes only patients who receive antipsychotic medications from VA pharmacies.
We collected data on patient age, gender, ethnicity, income, and service-connected status from the outpatient care file, which contains information about each day of outpatient care in the VA. Finally, data describing facility characteristics were taken from the National Mental Health Program Performance Monitoring System, which, in turn, is based on a variety of national VA data bases (Rosenheck etal. 2001) .
Measures. For each patient, the last prescription for an antipsychotic medication filled during FY 2000 was identified as the index prescription. All prescriptions for antipsychotic medications filled (both new prescriptions and refills) during the week prior to the index prescription were then identified. Because it is possible for prescriptions for concurrent medications to be filled on different days, we examined prescriptions over a 1-week window in order to identify all medications that a patient was taking at one time.
There are two broad classes of antipsychotic medications: conventional and atypical. Because they work in different ways, we used different methods to determine whether dosages complied with PORT dosing recommendations. For the conventional antipsychotics, we calculated chlorpromazine (CPZ) equivalents for each prescription based on the updated PORT dosing algorithms (A. Lehman, personal communication, May 2002) . CPZ equivalents were summed over all conventional antipsychotic prescriptions during the week to assess adherence to treatment recommendations. The PORT dosing recommendations have two ranges: one for maintenance therapy, and one for acute therapy. To be conservative, we used the range for acute therapy because it is wider. If the total daily CPZ equivalent for all conventional antipsychotics prescribed during the week was outside of the PORT-recommended range (300-1,000 mg per day), the patient was identified as being dosed too low or too high. For the atypical antipsychotics, the total daily dosage for each medication prescribed during the week was calculated. If the total dosage of any atypical was outside of the PORT-recommended range, the patient was identified as being dosed too low or too high. The PORT-recommended doses for atypical antipsychotic medications are as follows: clozapine 150 to 600 mg/day, olanzapine 5 to 20 mg/day, quetiapine 150 to 750 mg/day, and risperidone 2 to 6 mg/day. Patients who were prescribed two or more atypical medications or an atypical and a conventional (polypharmacy) were excluded from the analyses. Conventional antipsychotics were lumped together as a group because years of experience with these medications have shown that they are not significantly different from each other in terms of efficacy (Dixon et al. 1995; Arana and Rosenbaum 2000; Lieberman and Tasman 2000) . Hence, patients who received two or more conventional drugs were not considered to have polypharmacy and were included in the analyses.
Analysis. First, we determined the proportion of patients with the following characteristics: (1) those who were dosed within the PORT-recommended dosing range, (2) those who were dosed above the recommended range, and (3) those who were dosed below the recommended range. Next, we used multivariate regression analysis to identify patient, facility, and provider characteristics that affect each of these measures. Patient characteristics used in the models included whether the patient was aged 65 and older and the patient's gender, ethnicity, and income. Dichotomous variables were also included describing whether the patient had another primary or secondary diagnosis of mental illness in addition to a diagnosis of schizophrenia during 1999. Patients with other comorbid mental health diagnoses may be more severely ill and difficult to treat, which again could affect choice of pharmacotherapy. Diagnoses were based on ICD-9 diagnostic codes and included the following: Alzheimer's disease or dementia, substance abuse, major depression, bipolar disorder, posttraumatic stress disorder (PTSD), dysthymia, anxiety disorder, adjustment reaction, personality disorder, other psychosis, and other mental health disorders. ICD-9 diagnostic codes corresponding to these disorders are reported in the appendix. The degree of VA service-connected disability was categorized as 50 percent or more, less than 50 percent, or not service connected; the last category was omitted as the reference group. We dichotomized this variable because although there is a continuum between 0 and 100 percent, most patients are grouped at the ends of the spectrum. Finally, we included dichotomous variables describing whether the patient was prescribed any of the four atypical antipsychotic medications (conventionals as a group was the omitted reference group) to determine whether patients prescribed one drug were more or less likely to adhere to dosing recommendations than those receiving other drugs.
The facility characteristics included in the model were the size of the facility, as measured by the number of fulltime equivalent personnel; the degree to which the facility specialized in mental health care, as measured by the proportion of total costs accounted for by mental health care services; and the degree to which the facility had an academic emphasis, as measured by the proportion of total costs spent on research and education. Our hypotheses were that hospitals that were larger, that specialized in mental health care, or that had more of an academic emphasis might be more aware of dosing recommendations and guidelines and hence more likely to dose according to the PORT recommendations.
Characteristics of the prescribing provider included whether the provider was a physician and whether the provider was a mental health specialist. Mental health providers included psychiatrists, counselors, and therapists. Three dichotomous variables were included in the regression models corresponding to whether the provider was a physician mental health specialist (a psychiatrist), a non-mental health specialist physician (a nonpsychiatrist M.D.), or a nonphysician mental health specialist. Nonphysician non-mental health specialists were the omitted reference group.
Because patients are nested within facilities and both patient and facility characteristics are included in the regression models, the observations are not independent. To correct for the correlated nature of these data, the method of generalized estimation equations (GEE) was used in all analyses (Liang and Zeger 1986 ).
Results Table 1 shows characteristics of the sample. Only 33,304 (62.1%) of the 53,661 patients included in the sample were dosed according to the PORT recommendations. More patients were dosed below the recommendations (14,932, or 27.8%) than above (5,425, or 10.1%). Few of the patients in the sample were female (2,871 or 5.4%), which is characteristic of the VA population. The average annual income was $15,198, and 9,334 (17.4%) were aged 65 and over. Over half of the sample had a service-connected disability (30,683, or 57.2%), and most of these were service connected 50 percent or more (25,317, or 47.2% of the study sample). The most common comorbid conditions were substance abuse (11,803, or 22.0%) and bipolar disorder (8,151, or 15.2%) . The most commonly prescribed antipsychotic was conventionals as a class (20,434, or 38.1%), followed by olanzapine (16,262, or 30.3%) and risperidone (13,520, or 25.2%). Few patients received quetiapine (2,204, or 4.1%) or clozapine (1,077, or 2.0%). The majority of patients received their prescriptions from a psychiatrist (36,513, or 68.0%). Table 2 shows the results of the GEE regression models predicting adherence to PORT dosing recommendations. The first set of columns reports the results for the model with no interaction terms, and the second set of columns shows the results for the model with interactions of type of antipsychotic prescribed by the dichotomous variable indicating whether the patient was 65 and over. The results are consistent across the two models. Patients who were aged 65 and over or who were female were significantly less likely to adhere to PORT dosing recommendations. Patients who were service connected less than 50 percent, were treated by a nonpsychiatrist M.D., or had 
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Patient Outcomes Research Team; PTSD = posttraumatic stress disorcomorbid adjustment reaction, anxiety disorder, dysthymia, major depression, Alzheimer's/dementia, or PTSD disorders were also less likely to be dosed within treatment recommendations. Patients who were black or who received an atypical antipsychotic were more likely to be dosed according to recommendations. The interactions of age 65 and over with the atypical drugs were significantly positive for all but quetiapine, indicating that while older patients were less likely to adhere to recommendations, the effect was greater for those prescribed conventional drugs. None of the facility variables were significant. Table 3 reports the GEE regression results predicting whether the patient was dosed above the PORT recommendations among patients whose dose did not fall within the recommended range. Again, results are presented for models with and without interactions of age 65 and over with each of the atypical drugs, and the results were fairly consistent across the models. Patients who were black or service connected 50 percent or more were more likely to be dosed above the PORT-recommended range. Patients who were prescribed any of the atypical medications or who were treated in facilities with higher proportions of total costs spent on mental health or research and education were also more likely to be dosed above the recommendations. Patients aged 65 and over, females, patients who were less than 50 percent service connected, and patients with comorbid adjustment reaction, bipolar disorder, dysthymia, major depression, Alzheimer's/dementia, PTSD, or other mental health disorders were more likely to be dosed below the PORT-recommended range. The interactions of age 65 and over with prescription of clozapine, olanzapine, and risperidone were negative and significant, indicating that older patients prescribed these drugs were more likely to be dosed below the recommen- 
Discussion
This study investigated the determinants of adherence to the schizophrenia PORT dosing recommendations. While only 62 percent of patients diagnosed with schizophrenia who were prescribed an antipsychotic were dosed within the PORT-recommended range, provider and facility characteristics were generally not significantly associated with adherence to the recommendations. Patients prescribed atypical medications were more likely to be dosed according to recommendations, and those with comorbid mental health disorders were generally less likely to be dosed within the recommended range. The low rates of adherence are consistent with other studies. Studies by Lehman et al. (1998) and found that 62 percent and 74 percent, respectively, of patients diagnosed with schizophrenia are dosed within the PORT-recommended range. These studies, however, did not investigate patient and provider characteristics associated with guideline adherence. A previous study by Leslie and Rosenheck (2001c) found that older patients, minorities, and those with comorbid depression or substance abuse were generally less likely to receive multiple antipsychotics or be dosed above PORT recommendations and that neither academic emphasis nor fiscal stress (the change in per capita mental health costs during the previous 5 years) was significantly associated with adherence to recommendations. However, this study did not explicitly model adherence to dosing recommendations and did not investigate provider characteristics associated with the likelihood of dosing above or below PORT recommendations.
The strongest predictor of adherence to dosing recommendations and of dosing above the recommendations when the recommendations are not followed was prescription of an atypical antipsychotic medication. Patients prescribed atypicals were both more likely to adhere to recommendations and more likely to be dosed above the recommendations when their dose falls outside of the recommended range. Reciprocally, patients treated with conventionals were less likely to be dosed within recommendations and more likely to be dosed below recommendations when nonadherent. These findings may suggest either that the recommendations for atypicals are too low or that the recommendations for conventionals are too high.
Although being service connected 50 percent or more was not significantly associated with adherence to recommendations, these patients were more likely to be dosed above the recommendations when their dose was outside of the recommended range. This suggests that providers may be more aggressive with more severely ill patients. Such an approach may be clinically appropriate and suggests that the PORT recommendations may not be flexible enough to allow for differences in patient needs.
Female patients were less likely to be dosed within the PORT-recommended range and more likely to be dosed below the recommendations when their dose was outside of the recommended range. Black patients were more Likely to be dosed according to PORT guidelines but more Likely to be dosed above the recommendations when their dose was not within the PORT-recommended range. Patients with comorbid mental health conditions in general were less likely to be dosed according to PORT recommendations and were generally more likely to be dosed below the recommendations when they were dosed outside of the recommended range. While these results may not necessarily imply poor quality of care, clinicians should be aware that these populations are at greater risk of nonadherence to antipsychotic dosing recommendations.
In addition, patients treated at facilities with greater academic emphasis or specializing in mental health were also more likely to be dosed above the recommendations when their dose was outside of the PORT-recommended range. Because these facilities may be better equipped to treat more severely ill patients and because increasing the dose may be clinicaLLy appropriate for patients not responding to lower doses, this may not necessarily indicate poorquality care.
Lndeed, while the PORT recommendations should continue to evolve as clinical experience and research accumulate, the dosing recommendations are intended to be used only as a guide. The PORT recommendations indicate that dosing outside of this range may be clinically appropriate but that such doses need to be justified (Lehman et al. 1998) . Deviations from the dosing recommendations may highlight shortcomings of the recommendations or may help identify subgroups for whom the quality of care may be inadequate.
To explore how sensitive our results are to the dosing recommendations, we repeated our analyses using an alternative range of recommended doses (data available on request). Nasrallah and Smeltzer (2002) report the following dosing ranges for olanzapine, quetiapine, and risperidone based on practice patterns: olanzapine 15 to 30 mg/day, quetiapine 400 to 800 mg/day, and risperidone 4 to 6 mg/day. When these ranges are used, the number of patients whose dose adhered to recommendations decreases from 33,304 (62.1%) to 19,977 (37.2%). The decrease is entirely due to more patients being dosed below the recommendations: 28,259, or 52.7 percent. There were few changes, however, in the determinants of adherence to or being dosed above the recommended range. Some variables that were significant in the models using the PORT definitions were not significant in the models using the alternative dosing ranges, and vice versa. Facilities with a higher proportion of costs spent on mental health care were significantly more likely to adhere to the alternative dosing range, but none of the provider variables were significant. The only major difference between the two dosing ranges was that patients prescribed quetiapine were significantly less likely to be dosed within the range reported by Nasrallah and Smeltzer, whereas they were significantly more likely to be dosed according to the PORT dosing recommendations.
Some limitations of the analyses deserve comment. First, using administrative records to study patterns of pharmacotherapy can be difficult (Chen et al. 2000) . Prescriptions may last for varying lengths of time. Patients with multiple prescriptions may run out of their medications and need to see their doctor to refill different prescriptions at different times. We collected all prescription drug records during a 1-week period, but a longer time frame may be necessary to identify all of the drugs a particular patient is taking. As a result, our measure of whether a patient is dosed above PORT recommendations may be underestimated, and the fraction of patients dosed below the recommendations may be overestimated. In addition, some patients may be titrating either up or down and may not have reached their stable dose during the week that we chose for analysis. However, a longer time frame might have included prescriptions that had been discontinued. As physicians try different medications and dosages to find the optimal regimes for particular patients, they may advise patients to stop taking a previously prescribed medication and start taking a different drug. Because such instructions are not included in administrative pharmacy data, we could not take them into consideration in constructing our measures. Increasing the time period over which we examine prescriptions from 1 week to 4 weeks resulted in only very small changes in the proportion of patients who dosed outside of the PORT-recommended range. Hence, we believe that any bias in our results due to the 1-week window is small.
Administrative data also limit our ability to control for facility characteristics. Our measures of facility characteristics are rough and may not capture all of the relevant features of VA facilities that might affect antipsychotic prescribing patterns. Limitations with the data set also prevented us from including in our analyses measures of nonpsychiatric comorbidities, which might affect how antipsychotic medications can be dosed.
A final limitation is that we do not have information on depot medications. However, a previous study of antipsychotic use in the VA found that only 11.8 percent of outpatients received depot medications . Although this could affect our measure of the proportion of patients who were dosed below PORT recommendations, we feel that not being able to include depot medications in the analyses did not significantly affect the results.
Despite these limitations, it is clear that a considerable proportion of patients with schizophrenia are not prescribed doses of antipsychotic medications that comply with PORT recommendations. While it is not obvious whether this implies poor-quality care, these results raise concerns about dosing recommendations and patterns of pharmacotherapy. As clinicians gain experience with using these medications, guidelines may be refined and improved, and adherence to recommendations may increase. In the meantime, further research is needed to identify optimal dosing ranges, and standing treatment recommendations and guidelines should be used flexibly and with caution.
